Lin W.-SLai Y.-JKalyanam NHo C.-TMIN-HSIUNG PAN2021-07-262021-07-26202016134125https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096752839&doi=10.1002%2fmnfr.202000576&partnerID=40&md5=4d30004141deb173328d279099a0b95fhttps://scholars.lib.ntu.edu.tw/handle/123456789/572886Scope: The objective of the present study is to investigate whether edible S-allylcysteine (SAC) has chemoprophylactic effects on inflammation-associated colon carcinogenesis induced in mice through 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) exposure and promoted by dextran sodium sulfate (DSS) and whether its cancer-prevention effects are related to the modulation of gut microbiota composition. Methods and results: Dietary administration of 0.05% SAC in mice for 18 weeks prevents shortening of the colon length and reduces the number of colon polyps. The SAC supplementation markedly decreases PhIP/DSS-induced plasma and colon tissue pro-inflammatory cytokines. These changes are accompanied by the suppression of inducible nitric oxide synthase, COX-2, and MMP-2 protein expression in colon tissue. In addition, the dietary administration of SAC increases heme oxygenase-1 expression through activation of the NF-E2-related factor 2 pathway, thus abating PhIP/DSS-induced colitis. The 16S rRNA gene sequence data indicate that SAC counteracted the PhIP/DSS-induced gut dysbiosis, resulting in a microbiota composition similar to the control group. Conclusion: The results indicate that SAC can suppress PhIP/DSS-induced colorectal carcinogenesis. Hence, SAC may merit further clinical investigation as a chemoprevention strategy for retarding colitis-associated colon cancer in humans. ? 2020 Wiley-VCH GmbH2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; chemoprevention; colorectal cancer; S-allylcysteine[SDGs]SDG3journal article10.1002/mnfr.2020005762-s2.0-85096752839